Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
24 August 2018 Photo Igno van Niekerk
Chemistry changing the world to create a better future
These practical applications of Chemistry are part of the relevant and practically applicable research Prof André Roodt (far left) and his research group are involved in. With him are Dr Ebrahiem Botha, Post-doctoral fellow; Pheelo Nkoe, PhD student; Shaun Redgard, MSc student; and Dr Orbett Alexander, Post-doctoral fellow
Some people have a gift for explaining the most complex concepts in a way anyone could understand. Combine this gift with passion, energy, and enthusiasm, and you are close to describing a meeting with Prof André Roodt. 

Prof Roodt not only teaches Chemistry, he lives it. He has published more than 320 papers, lectured internationally more than 100 times, and has guided 35 PhD and 48 MSc students to complete their degrees. These figures are likely to conjure up visions of a dusty academic working on pie-in-the-sky theories. 

Adding value

Within minutes you are made aware of the fact that Chemistry is not only a subject confined to classrooms and labs. It is a means of changing the world through research to create a better future. In academic terms, Prof Roodt and his team are involved in ‘Homegeneous Catalysis’, ‘Radiopharmacy: Theranostics’, ‘Metal Benefication’, and ‘Conversion of carbon dioxide and water’. And just when you start to remember how terrifying high-school Chemistry was, Prof Roodt explains the practical nature of what they are doing.

Few of us are aware of the exact processes that produce fuel for our cars, although we probably know that these processes have side effects which are usually detrimental to the environment; but what if the by-products of these processes can be turned into speciality chemicals which could add value in different ways?

Ever wondered how medication know where to go in your body? Well – just imagine highly specialised (clever) pharmaceutical agents giving off their own ‘light’, knowing exactly where to go, showing you where they are going, and knowing what to do in order to provide information and interact with specific cells in your body to assist in healing cells and fighting disease. Exciting.

Passionate people

But, as they say in the ads, that is not all; imagine better ways to generate power, using the natural processes in plants to increase natural oxygen where needed, and to be able to change oxygen levels in the environment.

These practical applications of Chemistry are part of the relevant and practically applicable research Prof Roodt and his research group are involved in.

When you leave Prof Roodt’s office, you realise that this is what the UFS is all about: Global impact. World-class research. Passionate people. And seizing the opportunity to create the future.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept